PRESS-RELEASE filed Jun 8, 2026 at 01:00 ET
Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an oral BTK degrader, across oncology, immunology, and neurology. Nurix receives $700M upfront and is eligible for up to $2.3B in milestones, with 50/50 U.S. profit sharing and tiered royalties on ex-U.S. sales. This deal provides significant non-dilutive capital, validates Nurix's platform, and de-risks expansion into large indications like multiple sclerosis and chronic spontaneous urticaria, making it a transformative event for the company.